Purple Biotech Advances NT219 to Phase 2 for Head and Neck Cancer
Ticker: PPBT · Form: 6-K · Filed: Feb 18, 2025 · CIK: 1614744
Sentiment: bullish
Topics: clinical-trial, drug-development, oncology
TL;DR
Purple Biotech's NT219 drug moves to Phase 2 for head and neck cancer trials.
AI Summary
On February 18, 2025, Purple Biotech Ltd. announced the advancement of its drug candidate NT219 into a Phase 2 clinical trial for head and neck cancer. This milestone is a significant step in the company's development pipeline for the treatment of this specific cancer type.
Why It Matters
This advancement into Phase 2 trials is a critical step for Purple Biotech, potentially validating NT219's efficacy and moving it closer to potential market approval for head and neck cancer patients.
Risk Assessment
Risk Level: medium — Advancing to Phase 2 trials is a positive step, but clinical trial success is inherently uncertain, and regulatory approval is still a long way off.
Key Players & Entities
- Purple Biotech Ltd. (company) — Registrant and filer of the report
- NT219 (drug_candidate) — Drug advancing to Phase 2 trial
- February 18, 2025 (date) — Date of the press release and filing
- Head and Neck Cancer (disease) — Indication for the Phase 2 trial
FAQ
What is the specific indication for the Phase 2 trial of NT219?
The Phase 2 trial of NT219 is for head and neck cancer.
What is the name of the company filing this report?
The company filing this report is Purple Biotech Ltd.
On what date was the press release regarding NT219 issued?
The press release was issued on February 18, 2025.
What is the SEC file number for Purple Biotech Ltd.?
The SEC file number for Purple Biotech Ltd. is 001-37643.
What previous names has Purple Biotech Ltd. used?
Purple Biotech Ltd. was formerly known as Kitov Pharma Ltd. and Kitov Pharmaceuticals Holdings Ltd.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on February 18, 2025 regarding PURPLE BIOTECH LTD. (PPBT).